Drug Approvals
What a Week, China's Troubles, Hypersonic Weapons, Earnings, FDA Drug Approvals
The lack of urgency at the FDA, as it is in the defense space, is alarming.
Glimmers of Hope in the Biotech Realm as M&A Activity Picks Up
A recent trio of acquisition deals indicates the doldrums in the sector may be over.
Merck Continues to Reward Buyers
Investors are using the available weakness to buy the stock.
A Day Never to Forget, Red-Hot Debt Market, Moderna Marches On, Biden Thumbs Up
Plus, Zscaler largely delivers for its owners with its latest results.
There's Good News for 3 Biotech Names
And It comes after one of the best days of the year for the biotech sector.
Would-Be Buyers Should Wait for a Dip in Bullish Prothena
The shares of the under-the-radar biotech have had a strong run in recent months, so traders might want to watch for a pullback to buy.
Jim Cramer: Why Hasn't the Government Pushed for Mass Vaccination?
Incompetence, omissions and even outright lies have categorized this federal attempt to 'stem' the pandemic.
Jim Cramer: This Rally Is Squarely on Pfizer's Comirnaty
This COVID-19 vaccine is the potential savior of more than just the market.
Jim Cramer: The Drug Cos. Are at Full Strength
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.